Action and Reaction: the Biological Response to SiRNA and Its Delivery Vehicles

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2012 Jan 19

PMID 22252451

Citations 98

Authors

Rosemary L Kanasty

Kathryn A Whitehead

Arturo J Vegas

Daniel G Anderson

Affiliations

Soon will be listed here.

Abstract

RNA interference (RNAi)-based therapeutics have significant potential for the treatment of human disease. Safe and effective delivery of RNA to target tissues remains a major barrier to realizing its clinical potential. Several factors can affect the in vivo performance of short interfering RNA (siRNA) delivery formulations, including siRNA sequence, structure, chemical modification, and delivery formulation. This review provides an introduction to the principles underlying the pharmacokinetics and pharmacodynamics of systemically administered siRNA and its delivery formulations, including the factors that lead to its degradation, clearance, and tissue uptake, as well as its potential for immunogenicity, toxicity, and off-target effects within the body.

Citing Articles

Antibody/siRNA Nanocarriers Against Wnt Signaling Suppress Oncogenic and Stem-Like Behavior in Triple-Negative Breast Cancer Cells.

Hoover E, Day E J Biomed Mater Res A. 2025; 113(1):e37867.

PMID: 39760151 PMC: 11800355. DOI: 10.1002/jbm.a.37867.

Nonviral targeted mRNA delivery: principles, progresses, and challenges.

He X, Li G, Huang L, Shi H, Zhong S, Zhao S MedComm (2020). 2025; 6(1):e70035.

PMID: 39760110 PMC: 11695212. DOI: 10.1002/mco2.70035.

Co-delivery of antioxidants and siRNA-VEGF: promising treatment for age-related macular degeneration.

Dias M, Cruz-Cazarim E, Pittella F, Baiao A, Pacheco A, Sarmento B Drug Deliv Transl Res. 2025; .

PMID: 39751765 DOI: 10.1007/s13346-024-01772-x.

Delivery Strategies of siRNA Therapeutics for Hair Loss Therapy.

Jin S, Sung J Int J Mol Sci. 2024; 25(14).

PMID: 39062852 PMC: 11277092. DOI: 10.3390/ijms25147612.

A novel multitargeted self-assembling peptide-siRNA complex for simultaneous inhibition of SARS-CoV-2-host cell interaction and replication.

Tuttolomondo M, Pham S, Terp M, Castillo V, Kalisi N, Vogel S Mol Ther Nucleic Acids. 2024; 35(3):102227.

PMID: 38939051 PMC: 11203390. DOI: 10.1016/j.omtn.2024.102227.

References

Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View

Layzer J, McCaffrey A, Tanner A, Huang Z, Kay M, Sullenger B . In vivo activity of nuclease-resistant siRNAs. RNA. 2004; 10(5):766-71. PMC: 1370566. DOI: 10.1261/rna.5239604. View

Langkjaer N, Pasternak A, Wengel J . UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg Med Chem. 2009; 17(15):5420-5. DOI: 10.1016/j.bmc.2009.06.045. View

Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Narayanannair Jayaprakash K . Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010; 18(7):1357-64. PMC: 2911264. DOI: 10.1038/mt.2010.85. View

Feve B, Bastard J . The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2009; 5(6):305-11. DOI: 10.1038/nrendo.2009.62. View

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Padera T, Kadambi A, Tomaso E, Carreira C, Brown E, Boucher Y . Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002; 296(5574):1883-6. DOI: 10.1126/science.1071420. View

Lim L, Lau N, Garrett-Engele P, Grimson A, Schelter J, Castle J . Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433(7027):769-73. DOI: 10.1038/nature03315. View

Leu A, Berk D, Lymboussaki A, Alitalo K, Jain R . Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000; 60(16):4324-7. View

10.

Mayor S, Pagano R . Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol. 2007; 8(8):603-12. PMC: 7617177. DOI: 10.1038/nrm2216. View

11.

Patrakka J, Tryggvason K . Molecular make-up of the glomerular filtration barrier. Biochem Biophys Res Commun. 2010; 396(1):164-9. DOI: 10.1016/j.bbrc.2010.04.069. View

12.

Akinc A, Goldberg M, Qin J, Dorkin J, Gamba-Vitalo C, Maier M . Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther. 2009; 17(5):872-9. PMC: 2835134. DOI: 10.1038/mt.2009.36. View

13.

Romberg B, Hennink W, Storm G . Sheddable coatings for long-circulating nanoparticles. Pharm Res. 2007; 25(1):55-71. PMC: 2190344. DOI: 10.1007/s11095-007-9348-7. View

14.

Boese Q, Leake D, Reynolds A, Read S, Scaringe S, Marshall W . Mechanistic insights aid computational short interfering RNA design. Methods Enzymol. 2005; 392:73-96. DOI: 10.1016/S0076-6879(04)92005-8. View

15.

Hillaireau H, Couvreur P . Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci. 2009; 66(17):2873-96. PMC: 11115599. DOI: 10.1007/s00018-009-0053-z. View

16.

Minshall R, Tiruppathi C, Vogel S, Malik A . Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochem Cell Biol. 2002; 117(2):105-12. DOI: 10.1007/s00418-001-0367-x. View

17.

Aird W . Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007; 100(2):158-73. DOI: 10.1161/01.RES.0000255691.76142.4a. View

18.

Huang Y, Hong J, Zheng S, Ding Y, Guo S, Zhang H . Elimination pathways of systemically delivered siRNA. Mol Ther. 2010; 19(2):381-5. PMC: 3034859. DOI: 10.1038/mt.2010.266. View

19.

Hashizume H, Baluk P, Morikawa S, McLean J, Thurston G, Roberge S . Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000; 156(4):1363-80. PMC: 1876882. DOI: 10.1016/S0002-9440(10)65006-7. View

20.

Brown K, Chu C, Rana T . Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol. 2005; 12(5):469-70. DOI: 10.1038/nsmb931. View